UCB SA (UCB.BR)
| Previous close | 119.90 |
| Open | 120.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 119.70 - 121.10 |
| 52-week range | 65.40 - 122.60 |
| Volume | |
| Avg. volume | 315,883 |
| Market cap | 22.982B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 68.81 |
| EPS (TTM) | 1.76 |
| Earnings date | 28 Feb 2024 |
| Forward dividend & yield | 1.36 (1.13%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | 125.30 |
PR NewswireUCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
PR NewswireUCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
PR NewswireFDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
